Holen Sie sich die Stockscreener-App
8.2628
0.49%
0.0228
Schlusskurs vom Vortag:
$8.24
Offen:
$8.31
24-Stunden-Volumen:
377.80K
Relative Volume:
0.26
Marktkapitalisierung:
$818.47M
Einnahmen:
$142.77M
Nettoeinkommen (Verlust:
$-80.04M
KGV:
-10.20
EPS:
-0.8103
Netto-Cashflow:
$-86.02M
1W Leistung:
-8.61%
1M Leistung:
-6.44%
6M Leistung:
-17.45%
1J Leistung:
-30.71%
1-Tages-Spanne:
$8.23
$8.50
1-Wochen-Bereich:
$8.15
$9.6512
52-Wochen-Spanne:
$6.66
$18.90
Ars Pharmaceuticals Inc Stock (SPRY) Company Profile
Firmenname
Ars Pharmaceuticals Inc
Sektor
Branche
Telefon
858-771-9307
Adresse
11682 EL CAMINO REAL, SUITE 300, SAN DIEGO
Compare SPRY vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SPRY
Ars Pharmaceuticals Inc
|
8.28 | 814.51M | 142.77M | -80.04M | -86.02M | -0.8103 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.30 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
743.20 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
696.47 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.53 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.27 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Ars Pharmaceuticals Inc Stock (SPRY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-04 | Fortgesetzt | Roth Capital | Buy |
| 2025-09-04 | Eingeleitet | Roth Capital | Buy |
| 2025-03-07 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-02-10 | Eingeleitet | Oppenheimer | Outperform |
| 2024-08-20 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-08-13 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2024-08-12 | Bestätigt | Leerink Partners | Outperform |
| 2024-07-25 | Eingeleitet | Raymond James | Outperform |
| 2024-03-05 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-02-20 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2023-09-20 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2023-01-31 | Eingeleitet | Wedbush | Outperform |
| 2023-01-03 | Eingeleitet | William Blair | Outperform |
| 2022-12-13 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Ars Pharmaceuticals Inc Aktie (SPRY) Neueste Nachrichten
How (SPRY) Movements Inform Risk Allocation Models - Stock Traders Daily
ARS Pharmaceuticals: Neffy's Slow Launch, No Guidance For 2026 Keep Me On Sidelines (SPRY) - Seeking Alpha
SPRY: Expanding neffy access, advancing urticaria trials, and strong global uptake drive future growth - TradingView
SPRY: Expanding neffy access and advancing urticaria trials drive growth, with strong global uptake - TradingView
Leerink raises ARS Pharmaceuticals stock price target on sales expansion - Investing.com Australia
Leerink raises ARS Pharmaceuticals stock price target on sales expansion By Investing.com - Investing.com South Africa
Earnings call transcript: ARS Pharmaceuticals beats Q4 2025 forecasts, stock rises - Investing.com India
ARS Pharmaceuticals Q4 2025 Earnings Call Transcript - MarketBeat
ARS Pharmaceuticals Q4 Earnings Call Highlights - MarketBeat
ARS Pharmaceuticals Announces Strong 2025 Financial Results and neffy® Commercial Launch Progress, Highlights Global Approvals and Market Expansion - Minichart
ARS Pharmaceuticals Inc (SPRY) Q4 2025 Earnings Call Highlights: Strong Market Entry and ... By GuruFocus - Investing.com Canada
ARS Pharmaceuticals (SPRY) Posts Q4 Loss of $0.42/Share as Revenue Jumps 332% YoY to $28.1M - AlphaStreet
ARS Pharmaceuticals outlines sales force expansion and digital strategy for neffy growth while maintaining SG&A in 2026 - MSN
ARS Pharmaceuticals, Inc. 2025 Annual Report: Business Overview, Risk Factors, and Strategy for Neffy Commercialization 49 - Minichart
ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Updates on neffy® Commercialization - Investing News Network
ARS Pharmaceuticals earnings beat by $0.01, revenue topped estimates - Investing.com Canada
ARS Pharmaceuticals, Inc. (SPRY) Posts Fourth Quarter Loss, Surpasses Revenue Projections - Bitget
ARS Pharmaceuticals (NASDAQ:SPRY) Releases Quarterly Earnings Results, Hits Estimates - MarketBeat
ARS Pharmaceuticals, Inc. (SPRY) Reports Q4 Loss, Beats Revenue Estimates - Yahoo Finance
Earnings Flash (SPRY) ARS Pharmaceuticals, Inc. Reports Q4 Revenue $28.1M - marketscreener.com
ARS Pharmaceuticals Reports 2025 Results and neffy Growth - TipRanks
ARS Pharmaceuticals Inc (NASDAQ: SPRY) announces that the regulatory approval timeline for its nasal spray epinephrine product Neffy in Canada has been clarified. - Bitget
ARS Pharmaceuticals 2025 10-K: $84.3M Revenue, $(1.74) EPS - TradingView
ARS Pharmaceuticals Q4 revenue beats expectations on strong neffy sales - TradingView
ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Updates on neffy® (epinephrine nasal spray) Commercialization - Yahoo Finance
Aug Levels: Will ARS Pharmaceuticals Inc. stock recover after earningsEarnings Beat & Free Reliable Trade Execution Plans - baoquankhu1.vn
Exploring ARS Pharmaceuticals's Earnings Expectations - Benzinga
What To Expect From ARS Pharmaceuticals Inc (SPRY) Q4 2025 Earni - GuruFocus
ARS Pharmaceuticals (SPRY) Expected to Announce Earnings on Monday - MarketBeat
ARS Pharmaceuticals, Inc. (SPRY): Analyst Consensus Sees 214% Upside Potential - DirectorsTalk Interviews
Raymond James reiterates Strong Buy on ARS Pharmaceuticals stock By Investing.com - Investing.com South Africa
ARS Pharmaceuticals, Inc. (SPRY) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - Finviz
Raymond James reiterates Strong Buy on ARS Pharmaceuticals stock - Investing.com
SPRY Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
SPRY PE Ratio & Valuation, Is SPRY Overvalued - Intellectia AI
ARS Pharmaceuticals (NASDAQ:SPRY) Upgraded at Zacks Research - MarketBeat
Can Growing Patient And Provider Adoption Of Neffy Propel ARS Pharma's Stock Upward? - Nasdaq
ARS Pharmaceuticals, Inc. (SPRY) Stock Analysis: Exploring A 213% Potential Upside - DirectorsTalk Interviews
ARS Pharmaceuticals receives European approval nod for children's nasal spray - Traders Union
Market Fear: Can ARS Pharmaceuticals Inc sustain earnings growth2025 Earnings Surprises & Risk Adjusted Swing Trade Ideas - baoquankhu1.vn
Returns Recap: Can ARS Pharmaceuticals Inc sustain earnings growthWeekly Stock Analysis & Reliable Price Breakout Signals - baoquankhu1.vn
ARS Pharmaceuticals Announces Conference Call and Webcast for its Fourth Quarter and Full Year 2025 Financial Results and Participation at Upcoming Conferences - Investing News Network
ARS Pharmaceuticals Announces Conference Call and Webcast - GlobeNewswire
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
Nasus Pharma Is Targeting a Validated Market With a Potentially Superior Intranasal Delivery Approach - GuruFocus
Levin Capital Strategies L.P. Increases Holdings in ARS Pharmaceuticals, Inc. $SPRY - MarketBeat
CenterBook Partners LP Invests $5.15 Million in ARS Pharmaceuticals, Inc. $SPRY - MarketBeat
How Recent Regulatory Twists Are Reframing The Story For ARS Pharmaceuticals (SPRY) - Yahoo Finance
How Ars Pharmaceuticals Inc. (SPRY) Affects Rotational Strategy Timing - Stock Traders Daily
ARS Pharmaceuticals (NASDAQ:SPRY) Shares Up 7%Here's What Happened - MarketBeat
Practice Advances: A focus on neffy® (epinephrine nasal spray) - Patient Care Online
Finanzdaten der Ars Pharmaceuticals Inc-Aktie (SPRY)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.41%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):